330 related articles for article (PubMed ID: 23211740)
1. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.
Marcucci F; Bellone M; Rumio C; Corti A
MAbs; 2013; 5(1):34-46. PubMed ID: 23211740
[TBL] [Abstract][Full Text] [Related]
2. Using monoclonal antibodies to stimulate antitumor cellular immunity.
Durrant LG; Pudney VA; Spendlove I
Expert Rev Vaccines; 2011 Jul; 10(7):1093-106. PubMed ID: 21806402
[TBL] [Abstract][Full Text] [Related]
3. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
[TBL] [Abstract][Full Text] [Related]
4. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
Shimodaira H; Komine K; Soeda H; Ishioka C
Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
[TBL] [Abstract][Full Text] [Related]
5. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
Alderson KL; Sondel PM
J Biomed Biotechnol; 2011; 2011():379123. PubMed ID: 21660134
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Antibodies Can Drive Therapeutic T Cell Responses.
Wittrup KD
Trends Cancer; 2017 Sep; 3(9):615-620. PubMed ID: 28867165
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Carvalho S; Levi-Schaffer F; Sela M; Yarden Y
Br J Pharmacol; 2016 May; 173(9):1407-24. PubMed ID: 26833433
[TBL] [Abstract][Full Text] [Related]
8. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
9. Complement and cellular cytotoxicity in antibody therapy of cancer.
Wang SY; Weiner G
Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
[TBL] [Abstract][Full Text] [Related]
10. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
[TBL] [Abstract][Full Text] [Related]
11. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.
Velders MP; van Rhijn CM; Oskam E; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1998 Aug; 78(4):478-83. PubMed ID: 9716030
[TBL] [Abstract][Full Text] [Related]
12. [An overview of antibody therapy against cancer].
Taniguchi H; Imai K
Nihon Rinsho; 2012 Dec; 70(12):2087-92. PubMed ID: 23259378
[TBL] [Abstract][Full Text] [Related]
13. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
14. Emerging immunologic approaches to treatment of neoplastic diseases.
Olsson L; Mathé G
Recent Results Cancer Res; 1982; 80():334-7. PubMed ID: 6977172
[TBL] [Abstract][Full Text] [Related]
15. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Ferris RL; Jaffee EM; Ferrone S
J Clin Oncol; 2010 Oct; 28(28):4390-9. PubMed ID: 20697078
[TBL] [Abstract][Full Text] [Related]
16. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
18. Biological impediments to monoclonal antibody-based cancer immunotherapy.
Christiansen J; Rajasekaran AK
Mol Cancer Ther; 2004 Nov; 3(11):1493-501. PubMed ID: 15542788
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor monoclonal antibodies in conjunction with β-glucans: a novel anti-cancer immunotherapy.
Xiang D; Sharma VR; Freter CE; Yan J
Curr Med Chem; 2012; 19(25):4298-305. PubMed ID: 22834812
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
